621 related articles for article (PubMed ID: 33752741)
21. No Statistically Apparent Difference in Antiviral Effectiveness Observed Among Ribavirin Plus Interferon-Alpha, Lopinavir/Ritonavir Plus Interferon-Alpha, and Ribavirin Plus Lopinavir/Ritonavir Plus Interferon-Alpha in Patients With Mild to Moderate Coronavirus Disease 2019: Results of a Randomized, Open-Labeled Prospective Study.
Huang YQ; Tang SQ; Xu XL; Zeng YM; He XQ; Li Y; Harypursat V; Lu YQ; Wan Y; Zhang L; Sun QZ; Sun NN; Wang GX; Yang ZP; Chen YK
Front Pharmacol; 2020; 11():1071. PubMed ID: 32765274
[TBL] [Abstract][Full Text] [Related]
22. Early administration of lopinavir/ritonavir plus hydroxychloroquine does not alter the clinical course of SARS-CoV-2 infection: A retrospective cohort study.
Giacomelli A; Pagani G; Ridolfo AL; Oreni L; Conti F; Pezzati L; Bradanini L; Casalini G; Bassoli C; Morena V; Passerini S; Rizzardini G; Cogliati C; Ceriani E; Colombo R; Rusconi S; Gervasoni C; Cattaneo D; Antinori S; Galli M
J Med Virol; 2021 Mar; 93(3):1421-1427. PubMed ID: 32776534
[TBL] [Abstract][Full Text] [Related]
23. Effectiveness of early treatment of lopinavir-ritonavir in patients with severe COVID-19: a case series.
Luo P; Zheng JL; Liu Y; Qiu L; Liu XL; Xue HY; Liu D; Li J
Clin Med (Lond); 2021 Jan; 21(1):e80-e83. PubMed ID: 33355217
[TBL] [Abstract][Full Text] [Related]
24. Population pharmacokinetic analysis of lopinavir in HIV negative individuals exposed to SARS-CoV-2: a COPEP (COronavirus Post-Exposure Prophylaxis) sub-study.
Thoueille P; Delfraysse M; Andre P; Buclin T; Decosterd LA; Fedeli C; Ustero P; Calmy A; Guidi M;
BMC Pharmacol Toxicol; 2023 Sep; 24(1):47. PubMed ID: 37759315
[TBL] [Abstract][Full Text] [Related]
25. Comparative therapeutic efficacy of interferon alfa-2b and combination lopinavir/ritonavir plus interferon alfa-2b against SARS-CoV-2.
Liu J; Du C; Pu L; Xiang P; Xiong H; Xie W; Chen Z; Li A
BMC Infect Dis; 2021 Aug; 21(1):885. PubMed ID: 34461841
[TBL] [Abstract][Full Text] [Related]
26. Meta-analysis of arbidol versus lopinavir/ritonavir in the treatment of coronavirus disease 2019.
Yu M; Wang DC; Li S; Lei YH; Wei J; Huang LY
J Med Virol; 2022 Apr; 94(4):1513-1522. PubMed ID: 34837230
[TBL] [Abstract][Full Text] [Related]
27. Hydroxychloroquine as Postexposure Prophylaxis to Prevent Severe Acute Respiratory Syndrome Coronavirus 2 Infection : A Randomized Trial.
Barnabas RV; Brown ER; Bershteyn A; Stankiewicz Karita HC; Johnston C; Thorpe LE; Kottkamp A; Neuzil KM; Laufer MK; Deming M; Paasche-Orlow MK; Kissinger PJ; Luk A; Paolino K; Landovitz RJ; Hoffman R; Schaafsma TT; Krows ML; Thomas KK; Morrison S; Haugen HS; Kidoguchi L; Wener M; Greninger AL; Huang ML; Jerome KR; Wald A; Celum C; Chu HY; Baeten JM;
Ann Intern Med; 2021 Mar; 174(3):344-352. PubMed ID: 33284679
[TBL] [Abstract][Full Text] [Related]
28. Randomized controlled trial of the tolerability and completion of maraviroc compared with Kaletra® in combination with Truvada® for HIV post-exposure prophylaxis (MiPEP Trial).
Milinkovic A; Benn P; Arenas-Pinto A; Brima N; Copas A; Clarke A; Fisher M; Schembri G; Hawkins D; Williams A; Gilson R;
J Antimicrob Chemother; 2017 Jun; 72(6):1760-1768. PubMed ID: 28369381
[TBL] [Abstract][Full Text] [Related]
29. A randomized clinical trial comparing ritonavir-boosted lopinavir versus maraviroc each with tenofovir plus emtricitabine for post-exposure prophylaxis for HIV infection.
Leal L; León A; Torres B; Inciarte A; Lucero C; Mallolas J; Laguno M; Martínez-Rebollar M; González-Cordón A; Manzardo C; Rojas J; Pich J; Arnaiz JA; Gatell JM; García F;
J Antimicrob Chemother; 2016 Jul; 71(7):1982-6. PubMed ID: 26994091
[TBL] [Abstract][Full Text] [Related]
30. Epidemiologic Features and Clinical Course of Patients Infected With SARS-CoV-2 in Singapore.
Young BE; Ong SWX; Kalimuddin S; Low JG; Tan SY; Loh J; Ng OT; Marimuthu K; Ang LW; Mak TM; Lau SK; Anderson DE; Chan KS; Tan TY; Ng TY; Cui L; Said Z; Kurupatham L; Chen MI; Chan M; Vasoo S; Wang LF; Tan BH; Lin RTP; Lee VJM; Leo YS; Lye DC;
JAMA; 2020 Apr; 323(15):1488-1494. PubMed ID: 32125362
[TBL] [Abstract][Full Text] [Related]
31. A Randomized Clinical Trial of the Efficacy and Safety of Interferon β-1a in Treatment of Severe COVID-19.
Davoudi-Monfared E; Rahmani H; Khalili H; Hajiabdolbaghi M; Salehi M; Abbasian L; Kazemzadeh H; Yekaninejad MS
Antimicrob Agents Chemother; 2020 Aug; 64(9):. PubMed ID: 32661006
[TBL] [Abstract][Full Text] [Related]
32. High rate of major drug-drug interactions of lopinavir-ritonavir for COVID-19 treatment.
Macías J; Pinilla A; Lao-Dominguez FA; Corma A; Contreras-Macias E; González-Serna A; Gutierrez-Pizarraya A; Fernández-Fuertes M; Morillo-Verdugo R; Trigo M; Real LM; Pineda JA
Sci Rep; 2020 Dec; 10(1):20958. PubMed ID: 33262433
[TBL] [Abstract][Full Text] [Related]
33. Potential drug-drug interactions in COVID 19 patients in treatment with lopinavir/ritonavir.
Brandariz-Nuñez D; Correas-Sanahuja M; Guarc E; Picón R; García B; Gil R
Med Clin (Barc); 2020 Oct; 155(7):281-287. PubMed ID: 32718719
[TBL] [Abstract][Full Text] [Related]
34. Comparative effectiveness of Lopinavir/Ritonavir-based regimens in COVID-19.
Qu J; Li GH; Wang JJ; He GF; Huang JJ; Chen Y; Qu Q; Chen XY; Lu Q
Clin Exp Pharmacol Physiol; 2021 Feb; 48(2):203-210. PubMed ID: 33090501
[TBL] [Abstract][Full Text] [Related]
35. Pneumonia-targeted lopinavir/ritonavir-based treatment for patients with COVID-19: an early-period retrospective single center observational study.
Kim J; Jung J; Kim TH; Kang N; Choi H; Oh DH; Ahn MY; Kim SH; Hahm C; Lee YK; Park K; Hong K; Choi JP
BMC Infect Dis; 2021 Sep; 21(1):952. PubMed ID: 34521365
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and Safety of Lopinavir/Ritonavir or Arbidol in Adult Patients with Mild/Moderate COVID-19: An Exploratory Randomized Controlled Trial.
Li Y; Xie Z; Lin W; Cai W; Wen C; Guan Y; Mo X; Wang J; Wang Y; Peng P; Chen X; Hong W; Xiao G; Liu J; Zhang L; Hu F; Li F; Zhang F; Deng X; Li L
Med; 2020 Dec; 1(1):105-113.e4. PubMed ID: 32838353
[TBL] [Abstract][Full Text] [Related]
37. PEP-CoV protocol: a PEP flute-self-care randomised controlled trial to prevent respiratory deterioration and hospitalisation in early COVID-19.
Mollerup A; Larsen SC; Bennetzen AS; Henriksen M; Simonsen MK; Weis N; Kofod LM; Heitmann BL
BMJ Open; 2021 Jun; 11(6):e050582. PubMed ID: 34193503
[TBL] [Abstract][Full Text] [Related]
38. Lopinavir/ritonavir: Repurposing an old drug for HIV infection in COVID-19 treatment.
Magro P; Zanella I; Pescarolo M; Castelli F; Quiros-Roldan E
Biomed J; 2021 Mar; 44(1):43-53. PubMed ID: 33608241
[TBL] [Abstract][Full Text] [Related]
39. Hormonal intervention for the treatment of veterans with COVID-19 requiring hospitalization (HITCH): a multicenter, phase 2 randomized controlled trial of best supportive care vs best supportive care plus degarelix: study protocol for a randomized controlled trial.
Nickols NG; Goetz MB; Graber CJ; Bhattacharya D; Soo Hoo G; Might M; Goldstein DB; Wang X; Ramoni R; Myrie K; Tran S; Ghayouri L; Tsai S; Geelhoed M; Makarov D; Becker DJ; Tsay JC; Diamond M; George A; Al-Ajam M; Belligund P; Montgomery RB; Mostaghel EA; Sulpizio C; Mi Z; Dematt E; Tadalan J; Norman LE; Briones D; Clise CE; Taylor ZW; Huminik JR; Biswas K; Rettig MB
Trials; 2021 Jul; 22(1):431. PubMed ID: 34225789
[TBL] [Abstract][Full Text] [Related]
40. Umifenovir in hospitalized moderate to severe COVID-19 patients: A randomized clinical trial.
Alavi Darazam I; Shokouhi S; Mardani M; Pourhoseingholi MA; Rabiei MM; Hatami F; Shabani M; Moradi O; Gharehbagh FJ; Irvani SSN; Amirdosara M; Hajiesmaeili M; Rezaei O; Khoshkar A; Lotfollahi L; Gachkar L; Dehbsneh HS; Khalili N; Soleymaninia A; Kusha AH; Shoushtari MT; Torabinavid P
Int Immunopharmacol; 2021 Oct; 99():107969. PubMed ID: 34273635
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
